Based on the CHI3L1 expression in ovarian cancer tissue, appropriate candidates can be selected to receive combinations of paclitaxel-platinum chemotherapy and other novel anti-apoptotic agents, especially Mcl-1. The gene discussed is MCL1; the disease is ovarian carcinoma.